Loading
POLE (DNA polymerase epsilon catalytic subunit A) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Ovarian cancer, Lung cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Catalytic component of the DNA polymerase epsilon complex. Participates in chromosomal DNA replication. Required during synthesis of the leading DNA strands at the replication fork, binds at/or near replication origins and moves along DNA with the replication fork. Has 3'-5' proofreading exonuclease activity that corrects errors arising during DNA replication. Involved in DNA synthesis during DNA repair. Along with DNA polymerase POLD1 and DNA polymerase POLK, has a role in excision repair (NER) synthesis following UV irradiation. Location: Nucleus (UniProt). Locus 12q24.33 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Colorectal cancer | 0.7-2% | Exonuclease (proofreading) domain hotspot mutation, ultramutated tumours | Pathogenic somatic POLE mutations in 66 of 6,517 colorectal cancers, 1.0%, across nine trials and cohorts (Domingo 2016). cBioPortal, counting only exonuclease hotspots (P286R, V411L, S297F, S459F and their neighbours): 52 of 7,237, 0.7%, in crc_msk_2026; 8 of 1,134 in crc_msk_2017; 11 of 534, 2.1%, in coadread_tcga_pan_can_atlas_2018; 6 of 224 in coadread_tcga_pub; 5 of 619 in coadread_dfci_2016; 12 of 1,015 in crc_sysucc_2022. The studies' own molecular subtype attributes agree: POLE in 8 of 1,134 (crc_msk_2017) and 13 of 1,468 (crc_eo_2020). | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"POLE" OR ABSTRACT:"POLE" OR TITLE:"DNA polymerase epsilon, catalytic subunit" OR ABSTRACT:"DNA polymerase epsilon, catalytic subunit" OR TITLE:"DNA polymerase epsilon catalytic subunit A" OR ABSTRACT:"DNA polymerase epsilon catalytic subunit A" OR TITLE:"POLE1" OR ABSTRACT:"POLE1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about POLE, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/pole.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/pole.json. Licence CC BY-NC 4.0.